Form 4: Silo Pharma CEO Eric Weisblum Granted 200,000 Stock Options Under Equity Incentive Plan

Silo Pharma, Inc. CEO Eric Weisblum has been granted 200,000 stock options with an exercise price of $0.429, vesting one year from the grant date.

Summary

• Eric Weisblum, Chief Executive Officer and a Director of Silo Pharma, Inc. (SILO), was granted 200,000 stock options.
• The options have an exercise price of $0.429 per share.
• The grant date for these options was May 23, 2025.
• These options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan.
• One hundred percent (100%) of the shares subject to the option will vest on the one (1)-year anniversary of the grant date, specifically May 23, 2026.
• The options have an expiration date of May 23, 2035.
• Following this transaction, Eric Weisblum beneficially owns 387,932 derivative securities (options).

Sentiment

Score: 7

Explanation: The grant of stock options to the CEO is generally viewed positively as it aligns management's interests with long-term shareholder value, though it's a routine compensation event and not indicative of new operational performance.

Positives

• The grant of stock options to the CEO aligns management's financial interests with the long-term performance and shareholder value creation of Silo Pharma, Inc.
• The options were granted under an existing and approved 2020 Omnibus Equity Incentive Plan, indicating a structured and governed approach to executive compensation.

Future Outlook

The options granted to the CEO are set to vest on May 23, 2026, which will increase his exercisable equity holdings in the company at that time.

Industry Context

The grant of stock options to a Chief Executive Officer is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive compensation packages designed to incentivize long-term performance and align leadership interests with shareholder returns.

Comparison to Industry Standards

• The use of stock options as a form of executive compensation is a standard practice across publicly traded companies, including those in the pharmaceutical sector.
• The vesting schedule of one year is a common, though not universal, period for initial option grants, aiming to retain executives and incentivize sustained performance.

Corporate Governance

Related Party Transactions

• Grant of 200,000 stock options to Eric Weisblum, the Chief Executive Officer and a Director of Silo Pharma, Inc., which constitutes a transaction with a related party.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options, but also increased alignment of management incentives with shareholder value, potentially leading to improved long-term performance.
• Employees: Reflects the company's compensation strategy for key executives, which can influence overall compensation philosophy and morale.

Next Steps

• The options will vest on May 23, 2026, at which point Eric Weisblum will be able to exercise them.

Key Dates

Recommendation

Keywords

Silo Pharma, SILO, Stock Options, Executive Compensation, CEO, Equity Incentive Plan, Insider Transaction, Form 4, Beneficial Ownership